<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00683202</url>
  </required_header>
  <id_info>
    <org_study_id>56/2001</org_study_id>
    <nct_id>NCT00683202</nct_id>
  </id_info>
  <brief_title>Low-Dose Aspirin in in Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI) Treatments</brief_title>
  <official_title>The Significance of Low-Dose Aspirin on Ovarian Responsiveness, Uterine Hemodynamics and Pregnancy Outcome in in Vitro Fertilization and in Intracytoplasmic Sperm Injection: A Randomized, Placebo-Controlled Double-Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oulu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kuopio University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Tampere</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Oulu</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we hypothesized that low-dose aspirin therapy (100 mg daily) improves ovarian
      responsiveness, uterine haemodynamics and clinical pregnancy rates in unselected subjects
      undergoing IVF/ICSI when the treatment is started concomitantly with controlled ovarian
      hyperstimulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low-dose acetylsalicylic acid irreversibly inhibits the cyclo-oxygenase enzyme in platelets,
      thus preventing the synthesis of thromboxane, which causes vasoconstriction and platelet
      aggregation. By this mechanism low-dose aspirin may enhance ovarian and uterine blood flow
      and tissue perfusion and thus improve ovarian responsiveness for gonadotrophins and
      endometrial receptivity for implantation. Randomized controlled studies and meta-analyses on
      the low-dose aspirin therapy to improve IVF/ICSI outcome or uterine hemodynamics have
      revealed conflicting results.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2001</start_date>
  <completion_date type="Actual">March 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>Five weeks after embryo transfer</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uterine artery and spiral artery pulsatility index values</measure>
    <time_frame>On the day of embryo transfer</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">374</enrollment>
  <condition>Pregnancy</condition>
  <condition>Miscarriage Less Than 12 Gestational Weeks</condition>
  <condition>Extrauterine Pregnancy</condition>
  <condition>Preeclampsia</condition>
  <condition>Intrauterine Fetal Growth Restriction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Acetylsalicylic acid 100 mg daily perorally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo daily perorally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetylsalicylic acid</intervention_name>
    <description>Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Low-dose aspirin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age &lt; 40 years

          -  &lt; 4 previous ovarian stimulations

        Exclusion Criteria:

          -  allergy for acetylsalicylic acid
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mervi Haapsamo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of Oulu, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juha Rasanen, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Oulu, Finland and Oregon Health Sciences University, Oregon USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hannu Martikainen, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Oulu, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juha S Tapanainen, Prof</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Oulu, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seppo Heinonen, Prof</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital of Kuopio, Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helena Tinkanen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Unversity Hospital of Tampere, Finland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Oulu, Department of Obstetrics and Gynecology</name>
      <address>
        <city>Oulu</city>
        <zip>90220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>March 2001</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2008</study_first_submitted>
  <study_first_submitted_qc>May 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2008</study_first_posted>
  <last_update_submitted>May 22, 2008</last_update_submitted>
  <last_update_submitted_qc>May 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>Mervi Haapsamo/MD</name_title>
    <organization>University Hospital of Oulu</organization>
  </responsible_party>
  <keyword>Assisted reproduction</keyword>
  <keyword>Ovarian response</keyword>
  <keyword>Uteroplacental hemodynamics</keyword>
  <keyword>Doppler ultrasonography</keyword>
  <keyword>Implantation rate</keyword>
  <keyword>Pregnancy rate</keyword>
  <keyword>Live birth rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Fetal Growth Retardation</mesh_term>
    <mesh_term>Pregnancy, Ectopic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

